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Abstract
Perforin gene (PRF1) mutations have been identified in some patients diagnosed with the familial form of
hemophagocytic lymphohistiocytosis (HLH) and in patients with lymphoma. The aim of the present study was to
determine whether patients with a familial aggregation of hematological malignancies harbor germline perforin
gene mutations. For this purpose, 81 unrelated families from Tunisia and France with aggregated hematological
malignancies were investigated. The variants detected in the PRF1 coding region amounted to 3.7% (3/81). Two of
the three variants identified were previously described: the p.Ala91Val pathogenic mutation and the p.Asn252Ser
polymorphism. A new p.Ala 211Val missense substitution was identified in two related Tunisian patients. In order to
assess the pathogenicity of this new variation, bioinformatic tools were used to predict its effects on the perforin
protein structure and at the mRNA level. The segregation of the mutant allele was studied in the family of interest
and a control population was screened. The fact that this variant was not found to occur in 200 control
chromosomes suggests that it may be pathogenic. However, overexpression of mutated PRF1 in rat basophilic
leukemia cells did not affect the lytic function of perforin differently from the wild type protein.
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Background
Perforin is a Ca2+ dependent pore forming protein
stored as an active protein in specialized secretory lyso-
somes (known as lytic granules) of Cytotoxic T lympho-
cyte (CTL) and Natural Killer cells (NK). Upon
recognition of the target cells, lytic granules polarize
and release their contents at the immunologic synapse,
which triggers apoptosis [1,2]. Cytotoxic granules also
contain a group of serine proteases called granzymes in
a proteoglycan matrix [3,4]. Perforin is the only mole-
cule that is able to deliver granzymes into the target cell.
Perforin is encoded by PRF1, a highly conserved gene,
which is crucial to the function of the granzymes
involved in triggering caspase dependent and caspase
independent target cell death after the formation of an
immunological synapse [5]. Perforin-mediated cellular
cytotoxicity is a highly preserved mechanism responsible
for killing virus-infected and neoplastic cells.
PRF1 mutations were first described in familial hemo-
phagocytic lymphohistiocytosis (FHL) [6,7]. These muta-
tions include nonsense, frameshift and missense
mutations disrupting perforin activity [8-15]. FHL is a
life threatening disease usually occurring in childhood,
which is associated with profound immune derangement
and characterized by impaired T-cell and NK cell gran-
ule-mediated cytotoxic activity. The fact that these
mutations were described in homozygous and com-
pound heterozygous states suggests that autosomal
recessive transmission processes are involved. Patients
with FHL caused by biallelic perforin mutations are
severely immunocompromised [7,16].
Inherited PRF1 mutations were subsequently described
in various types of lymphomas [17-19], which suggests
that PRF1 protein is involved in the immune surveil-
lance mechanisms preventing tumor growth and/or
development.
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Escape from immune surveillance is thought to be the
main mechanism possibly explaining the role of some
predisposing genetic mutations in the development of
leukemia and lymphoma[20-23].
The key role of perforin in immune surveillance has
been extensively investigated using perforin knockout
(PRF1-KO) mice, which show high sensitivity to several
viral infections. These PRF1-KO mice develop sponta-
neous and aggressive disseminated B-cell lymphoma,
and fail to efficiently reject many transplanted tumors
[24-27].
Nevertheless, some previous studies have shown that
hematological neoplasms can be transmitted vertically,
which suggests that a predisposition may be caused by
an inherited genetic factor with incomplete penetrance
and pleitropic effects [28,29]. In view of these experi-
mental findings, we tested the hypothesis that some
patients with familial hematological malignancies might
harbor perforin gene mutations. PRF1 germline muta-
tions were therefore analyzed in a panel of families with
aggregated hematological malignancies with or without
solid tumors.
Methods
Patients and control population
The entire PRF1 coding region was sequenced in 89
patients belonging to 81 independent families: 6 Tuni-
sian and 75 French families recruited via a national
cooperative network focusing on familial hematological
malignancies (call for proposal 2005) and the GenHem-
INSERM/DGRS Franco- Tunisian project, and this net-
work was supported by the French National Cancer
Institute (INCa). The cohort consisted of 71 patients
belonging to 63 familial forms of hematological malig-
nancy (at least two cases of hematological malignancy
with or without solid tumors had occurred in the
patients’ first, second or third degree relatives); 17
patients from 17 families with aggregated tumors where
one case of hematological malignancy had occurred in
the patients’ first, second or third degree relatives; and 1
patient who had a multiple primitive tumor with hema-
tological malignancy but no family history.
The genetic analysis was performed on genomic DNA
extracted from peripheral blood cells obtained during
complete remission. Informed consent was obtained
from the patients, relevant family members (healthy
relatives) or their legal guardian as required by the Hel-
sinki Declaration. In the only case where no peripheral
blood was available, tumoral DNA was prepared from
paraffin embedded sections as previously described
[30,31].
A control Tunisian population was recruited among
healthy blood donors. Blood samples were obtained
after the donors had given their informed consent.
Analysis of perforin gene mutations
Genomic DNA was extracted from whole blood with the
EZ1 DNA tissue kit (Qiagen, Hilden, Germany) in line
with the manufacturer’s instructions. The coding region
(exon 2 and 3) and the intron-exon junctions of the per-
forin were amplified using standard PCR methods. The
primer sequences are available upon request.
The amplified PCR products were column-purified
and both strands were sequenced using the BigDye Ter-
minator Cycle Sequencing Ready Reaction Kit v1.1
(Applied Biosystems- Foster City, USA) and loaded onto
an ABI Prism 3130 sequencer (Applied biosystems). The
sequence chromatograms obtained were compared with
the published human PRF1 gene sequence (Genebank
accession number M28393) using the SeqScape software
program v2.5 (Applied Biosystems).
To address the issue of the occurrence of the newly
observed PRF1 mutation c.632 C > T (p.Ala211Val) in
the general population, a series of 200 Tunisian control
chromosomes were examined.
In silico analysis
To predict the effects of non synonymous SNP (nsSNP)
at mRNA and amino acid levels, Align-GVGD, SIFT,
ESEfinder and ESErescue bioinformatic tools, provided
in the Alamut pack V2.0 http://www.interactive-biosoft-
ware.com. Align-GVGD is a program that uses the bio-
physical characteristics of amino acids combined with
protein multiple sequence alignments (Grantham varia-
tion and Grantham Deviation scores) to predict where
amino acid substitutions fall in a spectrum ranging from
enriched deleterious to enriched neutral, based on the
GV an GD scores (0 to > 200). The criteria were set at
GV = 0 and GD≥65, respectively [32]. The SIFT (Sorting
Intolerant from Tolerant) method predicts whether an
amino acid substitution affects protein function based
on sequence homology and the physical properties of
amino acids. Normalized probabilities of substitutions
are calculated under default settings and probabilities
≤0.05 are taken to be deleterious [33]. ESEfinder [34,35]
and ESErescue [36] are algorithms for analyzing several
potential splicing regulatory elements.
Cell cultures, cytotoxicity assays and perforin expression
The p.Ala211Val-PRF1 variant was generated using the
QuickChange Protocol (Stratagene) (forward primer -5’
CCAGCCCGTCTACCTCAGGC-, reverse primer -5’
GCCTGAGGTAGACGGGCTGG-). The wild-type
(WT) and mutant cDNA were cloned into the pIRES2-
EGFP (CLONTECH) expression vector. Effector rat
basophile leukaemia cells (RBL-2H3; ATCC) were cul-
tured and transiently transfected with either wild-type
or p.Ala211Val mutant variant, and populations of cells
with identical mean EGFP fluorescence were FACS
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sorted as previously described [37]. The resultant cells
were then surface labeled with anti-trinitrophenol IgE;
target Jurkat T cells were first loaded with 51 Cr and
then surface-labeled with trinitrobenzosulfonic acid, as
previously described [37]. RBL and Jurkat T cells were
subsequently mixed at various effector/target cell
ratios, and the supernatants were harvested after a 4-
hour period of incubation at 37°C. The 51 Cr released
was measured on a gamma counter. The percentage
rate of specific 51 Cr release was calculated using the
formula [(experimental value-spontaneous release)/
(total value-spontaneous release) ×100%]. This mutated
perforin was tested 3 times at E/T ratios of 30:1, 10:1
and 2:1.
Results
A search for PRF1 mutations was conducted in a total
number of 89 probands identified in familial cancer
clusters. The results of PRF1 screening are summarized
in Table 1. Based on comparisons between sequences
alignments, three different sequence variations were
detected in three patients belonging to unrelated
families: a new variant p.Ala211Val in exon 3 and two
previously reported variants, p.Ala91Val in exon 2 and
p.Asn252Ser in exon 3.
The patient from the Tunisian family F1 was a male
diagnosed at the age of 32 years with nodular sclerosis
Hodgkin lymphoma type II stage I. After being cured,
he relapsed 5 years and a half later, showing stage III Bb
Hodgkin lymphoma (HL). He developed bone metas-
tases and died one year later. The screening of PRF1 led
to the identification of a heterozygous missense point
mutation c.632 C > T in exon 3, which transformed the
Alanine in position 211 into Valine (p.Ala211Val).
When permissions were available, we also screened this
patient’s healthy relatives (individuals III2, IV1-7 and
V1-4 in Figure 1). The mutation was carried by his
healthy mother and was also detected in a healthy
brother and in one of his four healthy sons.
This proband had a female second cousin, who was
diagnosed at the age of 36 (in 1998) with HL stage IV B
b. She carried the same heterozygous missense mutation
(p.Ala211Val). The treatment failed, and she relapsed
twice, two and three years later, and died due to the
progression of the disease. Neither her sisters nor her
brother carry the mutation. Her parents’ marriage was
consanguineous (Figure 1).
The Align-GVGD and SIFT scores obtained on the p.
Ala211Val substitution (0.35 and Class C0 (GV: 353.86,
GD = 0), respectively) predicted no effect on the protein
structure. The Alanine residue at position 211 was not a
highly conserved amino acid (6/17 species Alamut V2.0)
and the Grantham score between Alanine and Valine
was 64, which is a relatively low score.
In addition, the 632C > T substitution is found to be
localized 100 bp downstream of the consensus splice
acceptor site. Changes in the exonic splicing enhancer



























4 F3 France 43 renal cancer,
Ichthyosis
F c.272 C > T p.Ala91Val FHM with
solid tumors
? Low homology
FHM familial hematological malignancies, HL Hodgkin lymphoma, NHL Non Hodgkin Lymphoma
Figure 1 F1 Family Pedigree. The PRF1 mutation is carried by the
proband’s healthy mother and was also detected in his healthy
brother and healthy son. The proband (Individual IV-2) had HL at
the age of 32 years. His cousin (Individual IV-6) had HL at the age of
36 years. Squares stand for male and circles, for female. Open
symbols represent unaffected persons, and closed symbols
represent affected persons. The asterisk indicates that a germline
PRF1 mutation was identified.
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pattern were observed only with ESE finder (the crea-
tion of a SRp55 motif scored 3.01 using ESEfinder).
No new hexamers were predicted in this position by
ESErescue. The in silico analysis of c.632 C > T there-
fore did not predict that this substitution was
deleterious.
In parallel, in order to investigate the occurrence of
the p.Ala211Val mutation in the population, 200 Tuni-
sian control chromosomes were screened for the PRF1
gene. Interestingly, the p.Ala211Val substitution was not
detected in any of the control cases.
This result combined with the particularly aggressive
course of the Hodgkin lymphoma in our two patients
prompted us to test whether the p.Ala211Val mutation
might play a pathogenic role by performing functional
test with transfection experiments. Recombinant p.
Ala211Val perforin was overexpressed in RBL cells and
its lytic capacity was compared with that of WT per-
forin. 51Cr-release cytotoxicity assays were performed
using p.Ala211Val perforin transfected RBL cells. The p.
Ala211Val substitution showed normal WT perforin and
lytic activity (Figure 2).
The patient from family F2, a French male diagnosed
at the age of 45 years with a non Hodgkin lymphoma
(NHL), showed a heterozygous mutation c.755 G > A in
exon 3 resulting in Asparagine being replaced by Serine
in position 252 (p.Asn252Ser). This patient had a twin
brother who died at the age of 2 from leukemia. The
familial anamnesis showed signs of gastric tumors
developed by the father and the grandfather at the age
of 54 and 50, respectively.
The patient from French family F3, a female diag-
nosed at 43 years with renal cancer and ichtyosis, had a
heterozygous mutation c.272 C > T in exon 2, where
the Alanine in position 91 had been transformed into
Valine (p.Ala91Val). Her family had suffered from multi-
ple occurrences of cancer, as a brother and a cousin
both developed chronic myeloid leukemia (CML) at the
age of 34 and 37 years, respectively. The brother died of
the disease.
Discussion
The rejection of many experimental cancers by CTLs
and NK cells is dependent on the pore forming protein
perforin. This protein plays an important role in main-
taining immune surveillance, which protects the organ-
ism from the development of lymphoproliferative
disorders in vivo. Therefore, mice lacking peforin are
profoundly immunodeficient and have an enhanced sus-
ceptibility to viral infection and cancer. In these experi-
mental animal models, the increased incidence of
lymphoma associated with perforin deficiency is concei-
vably due to a defective cytotoxic mechanism normally
involved in maintaining immune homeostasis: this may
favor the uncontrolled proliferation and development of
premalignant lymphoid cells which may thus acquire a
malignant phenotype. Stepp et al first suggested that in
humans, perforin deficiency is responsible for an acute
immune disregulation leading to HLH [6]. Based on
mutational analyses, other authors reported the occur-
rence of lymphomas including B-cell, T-cell non-Hodg-
kin lymphoma as well as Hodgkin disease and
autoimmune lymphoproliferative syndrome (ALPS) that
were associated with perforin gene mutations. Bolitho et
al recently established that perforin is involved in the
surveillance of B cell lymphomas, as opposed to perforin
loss being causative of lymphoma [20].
In the present study, the rate of occurrence of mis-
sense mutations in familial hematological malignancies
was found to be 3.7%. The p.Ala211Val missense muta-
tion detected in one Tunisian patient is a novel finding
in the perforin gene: this is the first time to our knowl-
edge that this variant has been described. The two other
substitutions, p.Ala91Val and p.Asn252Ser which were
identified in French patients, have been previously
described and largely investigated.
The p.Asn252Ser PRF1 variant was first reported in a
patient with FHL [6], and then identified in patient pre-
senting with ALPS and NHL [18]. A functional analysis
[38] and studies on a control population [19] have sug-
gested that the p.Asn252Ser variant may be a benign
polymorphism. p.Asn252Ser has since been proved to be
a neutral PRF1 polymorphism.
Figure 2 Normal function of perforin with a valine substitution
at residue 211. The line graph shows the lytic activity of A211V
perforin observed in 51Cr-release cytotoxicity assays using
transfected RBL cells and Jurkat target cells at the E/T ratios
indicated, and compares the putative perforin mutation A211V with
WT human perforin and a mutated control perforin. Data shown are
means ± SDs. Experiments were repeated three times.
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The p.Ala91Val PRF1 variant has been previously
reported in siblings with FHL and NHL [17,19], and in
patients with Dianzani autoimmune lymphoproliferative
disease [39] and aplastic anemia [40]. Here we identified
this mutation in a patient with renal cancer with a
family history of chronic myeloid leukemia (CML).
Functional studies have shown that the levels of expres-
sion of the p.Ala91Val PRF1 protein decreased in these
patients, resulting in partial loss of lytic capacity [41].
Due to an abnormal folding, the lytic activity of the
mutant protein on the target cells was found to decrease
10-fold in comparison with that of the WT protein.
However, the authors of the only studies available so far
on this topic stated that the p.Ala91Val mutation alone
did not suffice to cause the development of FHL type 2.
Another event seems to be necessary to produce clini-
cally significant effects. p.Ala91Val PRF1 may act as a
synergistic factor with other genetic mutations predis-
posing patients to a larger range of cancer types such as
renal cancer and CML, and these mutations may be
involved in common immune surveillance and tumor
escape mechanisms.
p.Ala91Val is the most common amino acid substitu-
tion identified in perforin, where the allele frequency
ranges between 3% and 17%. It has long been a highly
controversial case of polymorphism. It is an unusual
case because it significantly affects the stability and the
cytolytic activity of perforin due to the incorrect folding
of the protein. It has been established that the homozy-
gous mutation p.Ala91Val was carried by a large healthy
population in whom perforin wild type function was
preserved despite the presence of the p.Ala91Val
substitution.
The variant p.Ala211Val was described in 5 members
of one consanguineous Tunisian family; two of them
were second cousins suffering from Hodgkin’s Lym-
phoma. They died young. The probands were found to
carry this germline mutation in the heterozygous state.
The other family members are disease free mutation
carriers. The fact that this new p.Ala211Val allele was
not detected in any of the 200 control chromosomes
screened suggests the pathogenicity of this mutation.
However, the sequence alteration identified might also
constitute a rare and hitherto undescribed polymorph-
ism. Nonetheless, the present functional studies did not
yield any evidence of altered PRF1 function in cells with
overexpressed PRF1. This PRF1 variant does not predis-
pose its carriers to hematological malignancies.
Conclusions
The results obtained in this study show that monoallelic
PRF1 variants alone cannot be used as prognostic fac-
tors. However, these variants might contribute to the
background of genetic factors which have yet to be
identified. The new p.Ala211Val seems rather to be a
rare allele.
In the cohort studied here, no PRF1 mutations predis-
posing their carriers to the development of hematologi-
cal malignancies were identified. It is possible, however,
that a heterozygous variant of PRF1 might act as an
inherited risk factor in addition to other genetic varia-
tions (somatic or constitutional variations in a second
allele) and/or in the presence of environmental factors.
Epigenetic modifications have been described in mam-
malian genomes which have profound effects on gene
expression. It has been established, for example, that the
methylation of cytosine residues at CpG dinucleotides in
the promoter region favors tumor development [42].
The CpG island hypermethylation profile is specific to
certain subtypes of leukemia and lymphoma [43]. How-
ever, very little is known about the epigenetic of PRF1.
Lu et al [44] have established that DNA methylation
and chromatin structure participate in the regulation of
PRF1 expression, whereas Gao et al [45] have described
how demethylating treatment can suppress NK cell
cytolytic activity. It would be interesting to investigate
the epigenetic of PRF1 to complete our study.
As immune surveillance is believed to play a major
role in preventing tumor growth and/or the develop-
ment of autoimmune disorders, the range of clinical
manifestations associated with perforin mutations may
be wider than suspected so far. Additional still undis-
covered genetic defects, or possibly even environmental
factors may possibly contribute along with the PRF1
variant to predispose carriers of this mutation to the
development of familial hematological malignancies. We
now intend to screen PRF1 in tumoral DNAs and
extend our investigations to other cooperating genes.
Lymphocyte mediated apoptosis involves many mole-
cules such as Fas, Fas Ligand, Caspase 8 and Caspase10.
Together with PRF1, these genes are excellent candi-
dates, which we are investigating and currently analyzing
in familial cancer aggregations including hematological
malignancies.
The identification of predisposing genetic factors
would help to develop methods of genetic counseling
and genetic testing for patients with familial hematologi-
cal malignancies. Inherited molecular markers make it
possible to identify these high-risk individuals and the
family members at risk, as well as to enroll them in
appropriate screening protocols.
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